Recent advances of DNAzyme-based nanotherapeutic platform in cancer gene therapy  

作　　者：Wendi Huo Xiaona Li Bei Wang Haoran Zhang Jinchao Zhang Xinjian Yang Yi Jin 

机构地区：[1]College of Basic Medical Science,Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education,Key Laboratory of Pathogenesis Mechanism and Control of Inflammatory-autoimmune Diseases of Hebei Province,Hebei University,Baoding 071002,Hebei,China [2]College of Chemistry&Environmental Science,Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of the Ministry of Education,Chemical Biology Key Laboratory of Hebei Province,Institute of Life Science and Green Development,Hebei University,Baoding 071002,Hebei,Chin

出　　处：《Biophysics Reports》2020年第6期256-265,共10页生物物理学报（英文版）

基　　金：The work was supported by the National Natural Science Foundation of China(21603051);the Natural Science Foundation of Hebei Province(B2018201221,B2018201157);Hebei Youth top talent project,Key Projects of Education Department of Hebei Province(ZD2018036);Undergraduate Innovation and Entrepreneurship Training Program of Hebei University(2020351).

摘　　要：Deoxyribozyme(or denoted as DNAzyme),which is produced by in vitro screening technology,has gained extensive research interest in the field of biomedicine due to its high catalytic activity and structure identification.This review introduces the structural characteristics of RNA-cleaving DNAzyme and its application potential in cancer gene therapy,which plays a significant role in cancer-related gene inactivation by specifically cleaving target mRNA and inhibiting the expression of the corresponding protein.However,the low delivery efficiency and cellular uptake hindered the widespread usage of DNAzyme in gene therapy of cancers.Emerging nanotechnology holds great promise for DNAzyme to overcome these obstacles.This review mainly focuses on DNAzyme-based nanotherapeutic platforms in gene therapy of cancers,including oncogene antagonism therapy,treatment resistance gene therapy,immunogene therapy,and antiangiogenesis gene therapy.We also revealed the potential of DNAzymebased nanotherapeutic platforms as emerging cancer therapy approaches and their security issues.

关 键 词：DNAZYME Cancer therapy GENE-SILENCING NANOCARRIER 

分 类 号：R730.5[医药卫生—肿瘤]